As the integration partner in this EU funded project, Labman are delighted that PoCOsteo - an innovative point of care tool for assessing the risk of osteoporosis - has reached this stage in research and development.
The early detection of osteoporosis is key to its successful treatment. The PoCOsteo project aims to overcome the significant challenges presented by the typical DXA method used to measure bone health, including the limitations in results it provides as well as accessibility to it.
PoCOsteo has been developed alongside partners (Ghent University, Universitat Rovira i Virgili, Fraunhofer IMM, EMRI, Medizinische Universität Graz and microLIQUID) and the integration led by Labman’s Phil Biggs and Dan Lenartowicz at our HQ in North Yorkshire. Further investment and final clinical validations are the final goal for this Horizon 2020 project which we are so proud to have been a part of.
This has been a challenging but ultimately fruitful project and the many positive outcomes are testament to the drive, skills and determination of the European partners that make up this consortium.
Phill Biggs, EU Projects Lead